Clinical Applications of Minimal Residual Disease Assessments by Tumor-Informed and Tumor-Uninformed Circulating Tumor DNA in Colorectal Cancer.

Total Neoadjuvant Therapy In a cohort of 85 LARC patients (many of whom were treated with TNT) undergoing serial plasma ctDNA assessments, TNT showed a trend towards an increased tumor response (odds ratio or OR 2.9, 95% CI 0.8–12.3, p = 0.1178), but there was no association between pre-neoadjuvant therapy and post-neoadjuvant therapy ctDNA status and tumor response [ 57 ].

also in 53,322 other papers